Methimazole embryofetopathy

Methimazole embryopathy is a teratogenic embryofetopathy that results from maternal exposition to methimazole (MMI; or the parent compound carbimazole) in the first trimester of pregnancy. MMI is an antithyroid thionamide drug used for the treatment of Graves' disease. In the infant, MMI may result in choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomalies, congenital heart disease (such as ventricular septal defect), renal system malformations and aplasia cutis. Additional features that may be observed include facial dysmorphism (short upslanting palpebral fissures, a broad nasal bridge with a small nose and a broad forehead) and athelia/hypothelia.

Also known as: MMI/CMZ embryofetopathy, MMI/CMZ embryopathy, Methimazole/carbimazole embryofetopathy, Methimazole/carbimazole embryopathy, methimazole embryofetopathy, Methimazole antenatal exposure, fetal methimazole syndrome, foetal methimazole syndrome

4 clinical trials for this condition and its sub-types.